WILEY



EVALUATION OF ENZYME INHIBITORS IN DRUG DISCOVERY

A Guide for Medicinal Chemists and Pharmacologists

ROBERT A. COPELAND

Contents

Foreword xi
Preface xiii
Acknowledgments xvii

1. Why Enzymes as Drug Targets? 1

1.1 Enzymes Are Essential for Life 2
1.2 Enzyme Structure and Catalysis 5
1.3 Permutations of Enzyme Structure during Catalysis 10
1.4 Other Reasons for Studying Enzymes 14
1.5 Summary 18
References 19

2. Enzyme Reaction Mechanisms 21

2.1 Initial Binding of Substrate 21
2.2 Noncovalent Forces in Reversible Ligand Binding to Enzymes 23
2.2.1 Electrostatic Forces 23
2.2.2 Hydrogen Bonds 23
2.2.3 Hydrophobic Forces 24
2.2.4 van der Waals Forces 25
2.3 Transformations of the Bound Substrate 25
2.3.1 Strategies for Transition State Stabilization 27
2.3.2 Enzyme Active Sites Are Most Complementary to the Transition State Structure 32
2.4 Steady State Analysis of Enzyme Kinetics 34
2.4.1 Factors Affecting the Steady State Kinetic Constants 37
2.5 Graphical Determination of k_{cat} and K_M 40
2.6 Reactions Involving Multiple Substrates 42
2.6.1 Bisubstrate Reaction Mechanisms 42
2.7 Summary 46
References 47

3. Reversible Modes of Inhibitor Interactions with Enzymes 48

3.1 Enzyme–Inhibitor Binding Equilibria 48
3.2 Competitive Inhibition 51
3.3 Noncompetititive Inhibition 56
3.3.1 Mutual Exclusivity Studies 63

3.4 Uncompetitive Inhibition 67
3.5 Inhibition Modality in Bisubstrate Reactions 70
3.6 Value of Knowing Inhibitor Modality 72
3.6.1 Quantitative Comparisons of Inhibitor Affinity 72
3.6.2 Relating K_i to Binding Energy 73
3.6.3 Defining Target Selectivity by K_i Values 76
3.6.4 Potential Advantages and Disadvantages of Different Inhibition Modalities In Vivo 76
3.6.5 Knowing Inhibition Modality Is Important for Structure-Based Lead Optimization 79
3.7 Summary 80
References 80

4. Assay Considerations for Compound Library Screening 82

4.1 Defining Inhibition, Signal Robustness, and Hit Criteria 83
4.2 Measuring Initial Velocity 86
4.2.1 End-Point and Kinetic Readouts 88
4.2.2 Effects of Enzyme Concentration 90
4.2.3 Other Factors Affecting Initial Velocity 92
4.3 Balanced Assay Conditions 94
4.3.1 Balancing Conditions for Multisubstrate Reactions 97
4.4 Order of Reagent Addition 98
4.5 Use of Natural Substrates and Enzymes 100
4.6 Coupled Enzyme Assays 104
4.7 Hit Validation and Progression 105
4.8 Summary 108
References 109

5. Lead Optimization and Structure-Activity Relationships for Reversible Inhibitors 111

5.1 Concentration–Response Plots and IC_{50} Determination 113
5.1.1 The Hill Coefficient 117
5.1.2 Graphing and Reporting Concentration–Response Data 121
5.2 Testing for Reversibility 125
5.3 Determining Reversible Inhibition Modality and Dissociation Constant 128
5.4 Comparing Relative Affinity 131
5.4.1 Compound Selectivity 132
5.5 Associating Cellular Effects with Target Enzyme Inhibition 133
5.5.1 Cellular Phenotype Should Be Consistent with Genetic Knockout or Knockdown of the Target Enzyme 134
5.5.2 Cellular Activity Should Require a Certain Affinity for the Target Enzyme 134

5.5.3 Buildup of Substrate and/or Diminution of Product for the Target Enzyme Should Be Observed in Cells 136
5.5.4 Cellular Phenotype Should Be Reversed by Cell-Permeable Product or Downstream Metabolites of the Target Enzyme Activity 137
5.5.5 Mutation of the Target Enzyme Should Lead to Resistance or Hypersensitivity to Inhibitors 138
5.6 Summary 139
References 139

6. Slow Binding Inhibitors 141

6.1 Determining k_{obs}: The Rate Constant for Onset of Inhibition 141
6.2 Mechanisms of Slow Binding Inhibition 145
6.3 Determination of Mechanism and Assessment of True Affinity 147
6.3.1 Potential Clinical Advantages of Slow Off-rate Inhibitors 153
6.4 Determining Inhibition Modality for Slow Binding Inhibitors 153
6.5 SAR for Slow Binding Inhibitors 155
6.6 Some Examples of Pharmacologically Interesting Slow Binding Inhibitors 156
6.6.1 Examples of Scheme B: Inhibitors of Zinc Peptidases and Proteases 156
6.6.2 Example of Scheme C: Inhibition of Dihydrofolate Reductase by Methotrexate 162
6.6.3 Example of Scheme C: Inhibition of Calcineurin by FKBP-Inhibitor Complexes 165
6.6.4 Example of Scheme C When $K_i^* << K_i$: Aspartyl Protease Inhibitors 166
6.6.5 Example of Scheme C When k_6 Is Very Small: Selective COX2 Inhibitors 169
6.7 Summary 176
References 177

7. Tight Binding Inhibitors 178

7.1 Effects of Tight Binding Inhibition Concentration–Response Data 179
7.2 The IC_{50} Value Depends on K_i^{app} and $[E]_T$ 180
7.3 Morrison's Quadratic Equation for Fitting Concentration–Response Data for Tight Binding Inhibitors 185
7.3.1 Optimizing Conditions for K_i^{app} Determination Using Morrison's Equation 187
7.3.2 Limits on K_i^{app} Determinations 188
7.3.3 Use of a Cubic Equation When Both Substrate and Inhibitor Are Tight Binding 189
7.4 Determining Modality for Tight Binding Enzyme Inhibitors 190
7.5 Tight Binding Inhibitors Often Display Slow Binding Behavior 192

7.6 Practical Approaches to Overcoming the Tight Binding Limit in Determining K_i 194
7.7 Enzyme-Reaction Intermediate Analogues as Examples of Tight Binding Inhibitors 197
7.7.1 Bisubstrate Analogues 202
7.7.2 Testing for Transition State Mimicry 203
7.8 Potential Clinical Advantages of Tight Binding Inhibitors 206
7.9 Determination of $[E]_T$ Using Tight Binding Inhibitors 209
7.10 Summary 211
References 212

8. Irreversible Enzyme Inactivators **214**

8.1 Kinetic Evaluation of Irreversible Enzyme Inactivators 215
8.2 Affinity Labels 219
8.2.1 Quiescent Affinity Labels 220
8.2.2 Potential Liabilities of Affinity Labels as Drugs 224
8.3 Mechanism-Based Inactivators 226
8.3.1 Distinguishing Features of Mechanism-Based Inactivation 228
8.3.2 Determination of the Partition Ratio 234
8.3.3 Potential Clinical Advantages of Mechanism-Based Inactivators 235
8.3.4 Examples of Mechanism-Based Inactivators as Drugs 236
8.4 Use of Affinity Labels as Mechanistic Tools 242
8.5 Summary 247
References 247

Appendix 1. Kinetics of Biochemical Reactions **249**

A1.1 The Law of Mass Action and Reaction Order 249
A1.2 First-Order Reaction Kinetics 252
A1.3 Second-Order Reaction Kinetics 255
A1.4 Pseudo–First-Order Reaction Conditions 256
A1.5 Approach to Equilibrium: An Example of the Kinetics of Reversible Reactions 257
References 259

Appendix 2. Derivation of the Enzyme–Ligand Binding Isotherm Equation **260**

References 263

Appendix 3. Serial Dilution Schemes **264**

Index **266**